GLA
MGX icon

Good Life Advisors’s Metagenomi Therapeutics MGX Stock Holding History

Good Life Advisors’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$296K Buy
200,000
+100,000
+100% +$157K 0.02% 405
2025
Q1 		$136K Sell
100,000
-25,000
-20% -$59.6K 0.01% 481
2024
Q4 		$451K Buy
+125,000
New +$302K 0.03% 306

Other funds holding MGX

SVGI
Sozo Ventures GP II Redwood City, California $1.33B AUM 9.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Good Life Advisors's MGX Position: Q2 2025 in Review

Good Life Advisors increased its Metagenomi Therapeutics (MGX) stake by 100% in Q2 2025, buying an estimated $157K and bringing the position to 200,000 shares worth $296K. The position accounts for 0.02% of the portfolio, ranked #405.

Good Life Advisors first reported a position in MGX in Q4 2024 and has held it in 3 quarters since. The position peaked at $451K in Q4 2024. 69 funds tracked by Wall St. Rank hold MGX as of Q2 2025.

  • Good Life Advisors held 200,000 shares of Metagenomi Therapeutics worth $296K as of Q2 2025.
  • Good Life Advisors bought 100,000 Metagenomi Therapeutics shares in Q2 2025, an estimated $157K.
  • Metagenomi Therapeutics made up 0.02% of Good Life Advisors's portfolio in Q2 2025, its #405 holding.
  • Good Life Advisors first reported a position in Metagenomi Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • Good Life Advisors's Metagenomi Therapeutics position peaked at $451K in Q4 2024.
  • 69 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2025.

Based on Good Life Advisors's 13F filing for Q2 2025, filed 8 Aug 2025.